ClinicalTrials.gg
Active, not recruitingNCT07233655Updated May 1, 2026

A Phase II Trial of SHR-3045 Injection in Patients With Rheumatoid Arthritis

A Phase 2 interventional study of SHR-3045 Injection and SHR-3045 Injection Placebo in Moderate to Severe Active Rheumatoid Arthritis, sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Arthritis, Rheumatoid by Jiangsu HengRui Medicine Co., Ltd. — none open to participants now, 1 under way, none of them phase 3. Arthritis, Rheumatoid · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
6th of 11
30 · median 30
Started
2026
the only one that year
Phase 2
2 of 11
none open now
Registered
11th of 11
by date

Among the 11 studies in Arthritis, Rheumatoid by Jiangsu HengRui Medicine Co., Ltd., this one is the 6th largest by enrollment, is the only one that started in 2026, is one of 2 in phase 2, and was the 11th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

None of the 11 studies in Arthritis, Rheumatoid by Jiangsu HengRui Medicine Co., Ltd. is open now. The open studies under Arthritis, Rheumatoid, anywhere →

Where they have run

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Arthritis, Rheumatoid by Jiangsu HengRui Medicine Co., Ltd. as a file.
02

Study summary

This study is ongoing to explore the efficacy and safety of different strengths of SHR-3045 injection in moderate to severe active rheumatoid arthritis.

03

Conditions studied

  • Moderate to Severe Active Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign the form before the start of activities related to this study, be able to understand the procedures and methods of this study, and be willing to strictly follow the clinical research protocol to complete this study.
  2. Age 18 to 75 years (including both ends) at the time of signing the informed consent form, with no gender restrictions.
  3. Suffer from moderate to severe active rheumatoid arthritis (RA).
  4. Have shown an inadequate response or intolerance to at least one conventional synthetic disease-modifying antirheumatic drug (csDMARD), biologic disease-modifying antirheumatic drug (bDMARD), or targeted synthetic disease-modifying antirheumatic drug (tsDMARD) during screening.
  5. Have a (BMI = weight (kg) / height² (m²)) of ≥ 18 kg/m² at the time of screening.

Exclusion criteria

Exclusion Criteria:

  1. General conditions: (1) Pregnant or breastfeeding women; (2) Have not used or refused to use the measures specified in the study protocol within 6 months after the last intake of medication (except for subjects or partners who are infertile); (3) Drug abuse; (4) The researcher judges that there are factors affecting the safety and efficacy evaluation of the study drug.
  2. Within 4 weeks prior to the random visit, the following conditions are identified in laboratory tests and 12-lead (ECG): (1) White blood cell count \< 3.0 × 10⁹/L; (2) \< 1.5 × 10⁹/L; (3) \< 90.0 g/L; (4) count \< 100 × 10⁹/L; (5) (ALT) or aspartate aminotransferase (AST) > 2 times the (ULN), or total (T-BIL) > 1.5 times the upper limit of normal (ULN); (6) Estimated (eGFR) calculated by the Modification of Diet in Renal Disease (MDRD) formula \< 60 mL/min/1.73 m² (see details in Section 13.4 of the Appendix); (7) (HbA1c) ≥ 8.0%; (8) Positive anti- virus (HCV) antibody with HCV RNA exceeding the upper limit of normal, positive (HIV) antibody, or positive syphilis antibody; (9) 12-lead ECG indicates abnormalities that may affect the safety of the subject, including but not limited to acute myocardial ischemia, myocardial infarction, severe arrhythmia, or significant prolongation (QTc > 500 ms).
  3. Any of the following medical histories or concurrent diseases exist: (1) Allergy to the study drug or any of its components; (2) Other systemic inflammatory diseases or diseases except rheumatoid arthritis (RA); (3) When screening, the subject's medical history, symptoms, and examination results indicate active tuberculosis or latent tuberculosis, and the subject's tuberculosis status will be screened through the γ interferon release assay (IGRA) and chest imaging examination; (4) History of non-tuberculous mycobacterial infection or opportunistic pathogen infection within 6 months before screening; (5) History of recurrent herpes zoster, disseminated herpes zoster or disseminated herpes simplex; (6) History of potential or active granulomatous inflammation, such as histoplasmosis, coccidioidomycosis, etc.; (7) History of chronic infection requiring treatment within 12 months before screening; (8) History of infection (viral, bacterial, fungal, parasitic) within 3 months before randomization, with hospitalization and/or parenteral systemic antimicrobial treatment; history of systemic antimicrobial treatment within 2 weeks before randomization; or open drainage wounds or ulcers at screening; or presence of joint prosthesis infection; (9) History of lymphoproliferative disorders; (10) History of malignant tumors or cancer; (11) Severe gastrointestinal diseases, or previous treatments that may affect drug absorption, history of gastrointestinal bleeding; (12) Moderate to severe congestive heart failure; (13) Uncontrolled grade 2 or higher hypertension; (14) History of thrombotic diseases within 12 months before randomization; (15) Cardiovascular or cerebrovascular events leading to hospitalization within 12 months before randomization; (16) History of organ transplantation; (17) Major surgery within 3 months before randomization, or planned major surgery during the study period; (18) Severe mental or neurological disorders or diseases (including alcoholism), unwillingness to communicate or language barriers, inability to fully understand and cooperate.
  4. The use of any of the following drugs or participation in clinical research (defined as signing the form): (1) Use of cytotoxic drugs; (2) Use of etanercept or etanercept biosimilar within 4 weeks before randomization; use of infliximab or infliximab biosimilar, adalimumab or adalimumab biosimilar, golimumab, certolizumab, tocilizumab, sarilumab, or abatacept within 8 weeks before randomization; use of rituximab within 1 year before randomization; (3) Use of other drugs known to have strong or immunomodulatory effects within 3 months before randomization, except for the above-mentioned drugs; (4) BCG vaccination within 12 months before screening; exposure to other or attenuated live vaccines within 3 months before randomization; or plan to receive live vaccines or attenuated live vaccines during the study period; (5) Participation in any other drug or medical device clinical research within 3 months before randomization or within 5 half-lives of the drug (whichever is longer); (6) Intramuscular or intravenous administration of within 4 weeks before randomization; (7) Intra-articular injection treatment (such as glucocorticoids, hyaluronic acid, etc.) within 4 weeks before randomization; (8) Use of traditional Chinese medicine preparations for the treatment of RA (such as Tripterygium wilfordii, total glucosides of paeony, sinomenine, etc.) or traditional Chinese medicine or Chinese patent medicine within 4 weeks before randomization; (9) Systemic interferon treatment within 4 weeks before randomization; (10) Use of strong opioids.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    SHR-3045 Injection Group

    SHR-3045 injection in different doses.

    Drug: SHR-3045 Injection

  • Placebo comparator
    SHR-3045 Injection Placebo Group

    SHR-3045 injection placebo in different doses.

    Drug: SHR-3045 Injection Placebo

Interventions

  • SHR-3045 injection.

  • DrugSHR-3045 Injection Placebo

    SHR-3045 injection placebo.

06

What researchers measure

Primary outcomes

  1. The percentage of subjects who achieved a 20% improvement in the American College of Rheumatology Rheumatoid Arthritis (RA) disease activity assessment core set.

    Time frame: After 14 weeks of treatment.

Secondary outcomes

  1. The percentage of subjects achieving a 20% improvement in the American College of Rheumatology (ACR) criteria for rheumatoid arthritis (RA) disease activity.

    Time frame: Within 169 days after administration.

  2. The percentage of subjects achieving a 50% improvement in the American College of Rheumatology (ACR) criteria for rheumatoid arthritis (RA) disease activity.

    Time frame: Within 169 days after administration.

  3. The percentage of subjects achieving a 70% improvement in the American College of Rheumatology (ACR) criteria for rheumatoid arthritis (RA) disease activity.

    Time frame: Within 169 days after administration.

  4. Changes in the 28-joint disease activity score (DAS28) levels from the baseline.

    Time frame: Within 169 days after administration.

  5. Changes in the C-reactive protein (CRP) levels from the baseline.

    Time frame: Within 169 days after administration.

  6. Changes in the erythrocyte sedimentation rate (ESR) levels from the baseline.

    Time frame: Within 169 days after administration.

  7. Changes in the simplified disease activity index (SDAI) score from the baseline.

    Time frame: Within 169 days after administration.

  8. Changes in the clinical disease activity index (CDAI) score from the baseline.

    Time frame: Within 169 days after administration.

  9. Adverse events (AEs).

    Time frame: Within 169 days after administration.

  10. Blood drug concentration of SHR-3045.

    Time frame: Within 169 days after administration.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2026 to primary completion in Apr 2026, 3 months.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 3 months is below that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Nov 18, 2025
StartActual
Jan 19, 2026
Primary completionActual
Apr 21, 2026
CompletionEst.
Jul 2026
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07233655
Responsible party
Sponsor
First posted
Nov 18, 2025
Start date
Jan 19, 2026
Primary completion
Apr 21, 2026
Completion
Jul 2026 (estimated)
Last update
May 1, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-3045

Start the discussion